ID rozhodnutia | ID návrhu | Stupeň | Typ rozhodnutia | Navrhovateľ | Zverejnené | Akcia |
---|---|---|---|---|---|---|
<< < 316 317 318 319 320 > >> | ||||||
R 228 | 723 | 1 | R_CND | Sanofi | 15.4.2012 | Detaily |
R 227 | 722 | 1 | R_CND | Sanofi -Aventis Deutschland GmbH | 15.4.2012 | Detaily |
R 226 | 715 | 1 | R_CND | Pfizer Europe MA EEIG | 15.4.2012 | Detaily |
R 225 | 713 | 1 | R_CND | Vipharm S.A. | 15.4.2012 | Detaily |
R 224 | 712 | 1 | R_CND | Sandoz GmbH | 15.4.2012 | Detaily |
R 223 | 711 | 1 | R_CND | Sandoz Pharmaceuticals d.d. | 15.4.2012 | Detaily |
R 222 | 710 | 1 | R_CND | EGIS Pharmaceuticals PLC | 15.4.2012 | Detaily |
R 221 | 699 | 1 | R_CND | GlaxoSmithKline Slovakia s.r.o. | 15.4.2012 | Detaily |
R 220 | 690 | 1 | R_CND | Grünenthal GmbH | 15.4.2012 | Detaily |
R 219 | 681 | 1 | R_CND | Generics (UK) | 15.4.2012 | Detaily |
R 218 | 679 | 1 | R_CND | Mylan, S.A.S | 15.4.2012 | Detaily |
R 217 | 670 | 1 | R_CND | Krka d.d. Novo mesto | 15.4.2012 | Detaily |
R 216 | 666 | 1 | R_CND | Glaxo Group Limited | 15.4.2012 | Detaily |
R 215 | 650 | 1 | R_CND | Gedeon Richter Plc. | 15.4.2012 | Detaily |
R 214 | 647 | 1 | R_CND | Boehringer Ingelheim International GmbH | 15.4.2012 | Detaily |
R 213 | 646 | 1 | R_CND | Medac Gesellschaft fur klinische Spezialpräparate mbH | 15.4.2012 | Detaily |
R 212 | 623 | 1 | R_CND | AstraZeneca AB | 15.4.2012 | Detaily |
R 211 | 612 | 1 | R_CND | Zaklady Farmaceutyczne POLPHARMA S.A. | 15.4.2012 | Detaily |
R 210 | 594 | 1 | R_CND | Accord Healthcare Polska Sp.z.o.o. | 15.4.2012 | Detaily |
R 209 | 530 | 1 | R_CND | Zaklad Farmaceutyczny Adamed Pharma SA | 15.4.2012 | Detaily |
R 208 | 529 | 1 | R_CND | GENERICON s.r.o. | 15.4.2012 | Detaily |
R 207 | 528 | 1 | R_CND | Adamed Sp. z o.o. | 15.4.2012 | Detaily |
R 206 | 527 | 1 | R_CND | Ranbaxy (UK) Limited | 15.4.2012 | Detaily |
R 205 | 508 | 1 | R_CND | Eli Lilly Nederland B.V. | 15.4.2012 | Detaily |
R 204 | 437 | 1 | R_CND | Allergan Pharmaceuticals Ireland | 15.4.2012 | Detaily |